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We previously identified Fam65b as an atypical inhibitor of the small G protein RhoA.
Using a conditional model of a Fam65b-deficient mouse, we first show that Fam65b
restricts spontaneous RhoA activation in resting T lymphocytes and regulates intranodal
T cell migration in vivo. We next aimed at understanding, at the molecular level,
how the brake that Fam65b exerts on RhoA can be relieved upon signaling to allow
RhoA activation. Here, we show that chemokine stimulation phosphorylates Fam65b
in T lymphocytes. This post-translational modification decreases the affinity of Fam65b
for RhoA and favors Fam65b shuttling from the plasma membrane to the cytosol.
Functionally, we show that the degree of Fam65b phosphorylation controls some
cytoskeletal alterations downstream active RhoA such as actin polymerization, as well
as T cell migration in vitro. Altogether, our results show that Fam65b expression and
phosphorylation can finely tune the amount of active RhoA in order to favor optimal T
lymphocyte motility.
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INTRODUCTION
Rho GTPases are involved in signaling pathways that regulate very broad biological functions
such as cell development, differentiation, and cytoskeletal alterations, in both physiological and
pathological conditions in many different cell types (1–3), including in immune cells (4–7).
Rho GTPases are considered as molecular switches because they oscillate between an inactive
GDP-bound state and an active GTP-bound form. This rapid cycle of activation-inactivation is
made possible by two classical families of regulatory proteins: Guanine nucleotide exchange factors
(GEFs) stimulate the GDP/GTP exchange, whereas GTPase activating proteins (GAPs) favor GTP
hydrolysis (8). In addition, another family of proteins called GDP dissociation inhibitors (GDI)
regulates the cytosol / plasma membrane localization of Rho GTPases (8).
In addition to these classic Rho GTPases regulators, a limited number of RhoA inhibitors that
do not contain typical GAP domains, have been described more recently. These include a vaccinia
virus -encoded protein called F11L (9) and a mammalian protein called Memo (10).
We were the first to show that the poorly studied Fam65b protein was also an atypical RhoA
partner that binds RhoA directly and inhibits its activation in T lymphocytes (11). This role
of Fam65b was further confirmed in neutrophils (12). Interestingly, Fam65a, an orthologue of
Fam65b, was also shown to decrease RhoA-GTP levels in HeLa cells (13). Although no study has
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reported any role for Fam65c so far, the current experimental
evidence gathered for the Fam65a and Fam65b members, point
toward a role for proteins of the Fam65 family in fixing a low
RhoA activity level in resting cells.
However, although resting T cells exhibit low RhoA-GTP
levels in part through Fam65a- and/or Fam65b-mediated
inhibition of RhoA activation, we know that many stimuli
received by cells are able to activate RhoA in a time frame when
Fam65b is still highly expressed. Thus, one might wonder which
mechanisms are at play in cells to allow the rapid neutralization
of the brake imposed by Fam65b on RhoA activation.
Here, we show that chemokine stimulation induces a
rapid Fam65b phosphorylation which decreases Fam65b-
RhoA binding, allows cytosolic localization of Fam65b,
and favors RhoA activation. This process is functionally
important to adjust RhoA activation levels because we
show that overexpressing Fam65b or knocking-out its
expression, impair T lymphocyte migration both in vitro and
in vivo.
RESULTS
Fam65b Inhibits Intranodal T Lymphocyte
Migration
In order to determine whether Fam65b controls T cell migration
in vivo, we generated a conditional murine model in which
Fam65b was specifically deleted in the T lymphocyte lineage
(Supplementary Figure 1). Fam65b was efficiently deleted in
knock-out (KO) mice as shown by the absence of both
Fam65b isoforms 1 and 2 in thymocytes and mature T
cells (Supplementary Figure 2A). As expected, the deletion of
Fam65b was only observed in the T cell lineage because non-
T cells obtained from KO mice expressed normal levels of
Fam65b (Supplementary Figure 2B). KO mice were perfectly
viable, fertile and did not exhibit any alteration in thymocyte
and T lymphocyte numbers in all the primary and secondary
lymphoid organs studied (Supplementary Figure 2C).
First, we identified the micro-anatomical location of
transferred T cells by performing ultra-short homing assays
followed by 3D lymph nodes reconstructions (14). Although
similar numbers of WT and KO T cells were observed inside
high endothelial venules (HEV), KO T cells exhibited a bias
compared to WT cells: KO T cells were more prone to reside
close to HEV than their WT counterparts (Figure 1A).
We next analyzed intranodal migration of wild-type (WT) or
Fam65bKO T cells using two-photon microscopy of anesthetized
mice as reported (16, 17). 24 h after injection of a mix of
fluorescently labeled WT and KO T cells, both populations were
compared for their single cell speed and the straightness of
their migratory trajectories into the lymph nodes parenchyma
in homeostatic conditions. Both the speed (Figure 1B) and
meandering index (Figure 1C) of KO T cells were reduced
indicating that in the absence of Fam65b, T lymphocytes
migrate more slowly and use less straight paths. Fam65b KO
T cells also exhibited a higher tendency to arrest (Figure 1D).
Accordingly, because of this reduced migration speeds and more
frequent changes in directionality, Fam65b KO T cells showed a
significantly lower motility coefficient (Figure 1E).
Fam65b Restricts Spontaneous RhoA
Activation in vivo
Based on our previous results and other studies showing that
Fam65a and Fam65b inhibit RhoA activity in vitro (11–13), we
next determined whether resting Fam65b KO T cells exhibit
alterations in RhoA-GTP levels.
By using an antibody that specifically recognizes active
RhoA, we were able to show, in homeostatic conditions, that
unchallenged resting T lymphocytes from Fam65bKO mice
exhibit a significant higher basal level of RhoA-GTP compared
to T cells purified from control WT littermates (Figure 2A, top).
This difference was not due to changes in total RhoA levels
(Figure 2A, bottom). Therefore, these results show that Fam65b
exerts a tonic inhibition on RhoA activity in primary resting
mouse T lymphocytes.
We next aimed at determining whether such a high level
of active RhoA observed in Fam65bKO T cells could lead to
downstream modifications of the RhoA signaling pathway. We
focused our analysis on the phosphorylation levels of myosin
light chains (MLC), as this process is known to be triggered
by the Rho-associated kinase ROCK, a key regulator of actin
organization and thus a regulator of cell migration downstream
active RhoA (18). In agreement with the higher RhoA-GTP levels
found in Fam65bKO T cells, our results clearly showed that KO
T cells have a higher content in active P-MLC than their WT
counterparts (Figure 2B).
Altogether, the aberrant and constitutively high levels of active
RhoA measured in resting KO T cells are most likely responsible
for the defects in intranodal migration reported here. These
results indicate that too much of RhoA-GTP inhibits T cell
migration, and show that Fam65b restricts spontaneous RhoA
activation in resting T cells. Nevertheless, in normal conditions
when WT T cells express Fam65b, it is well known that RhoA
becomes activated upon chemokine stimulation (11, 19). It is
not clear how the brake that Fam65b exerts on RhoA activation
can then be relieved to achieve an increase in RhoA-GTP levels
upon chemokine receptor signaling. We previously reported that
the strong and constitutive RhoA-Fam65b interaction in resting
T cells is transiently disrupted upon CCL19 stimulation (11).
Thus, we have next attempted to delineate further the molecular
mechanisms responsible for this RhoA-Fam65b dissociation.
Fam65b Phosphorylation Upon Chemokine
Stimulation Inhibits RhoA-Fam65b
Interaction
Western blot analysis of protein samples obtained from lysates
of T cells stimulated with CCL19 or CXCL12 showed that
both Fam65b isoforms migrated with a higher apparent
molecular weight in stimulated conditions (Figure 3A,
Supplementary Figure 3). These shifts were completely
abrogated when the protein lysates were treated with phosphatase
λ to remove all phosphate groups from the serine, threonine and
tyrosine amino acids. We even observed that Fam65b migrated
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FIGURE 1 | Fam65b inhibits T cell migration in vivo. T lymphocytes purified from WT or Fam65b KO mouse peripheral lymph nodes were loaded with distinct
fluorescent probes and injected at a ratio of 1:1 into a recipient wild-type mouse. (A) Left: Microscopic field showing WT (blue) or KO (red) T cells together with HEV
staining (gray). 1 unit scale = 8.6µm. Right: Percentage of lymph node WT or KO T cells retained near HEV in the perivascular region (peri) or located inside HEV
(intra) as described in (15). Distribution of single T cell speeds (B), meandering indexes (C) and arrest coefficients calculated for a threshold of 4 µm/min (D) are
shown. (E) Average displacement of cells according to the square root of time. The leading coefficient of this line is the coefficient of motility. **p < 0.01, ***p <0.001.
slightly lower than in the non-treated cells after the phosphatase
λ treatment, including in the unstimulated cells (Figure 3A, top).
These results show that Fam65b phosphorylation is strongly
increased upon chemokine stimulation in T lymphocytes. They
also suggest that Fam65 is already phosphorylated at a low level
in unstimulated resting T cells.
Using pull-down assays run in parallel, we next compared
the amount of RhoA associated with Fam65b in these different
conditions. We observed that upon CCL19 stimulation, RhoA
binding to Fam65b was lost. In contrast, phosphatase λ
treatment strongly increased this binding, suggesting that non-
phosphorylated Fam65b proteins are the most efficient RhoA
binders. Weakly phosphorylated Fam65b present in resting T
cells could also bind RhoA, although to a lesser extent.
Altogether, these results suggest a role for Fam65b
phosphorylation in controlling the ability of Fam65b to
bind RhoA.
This result was reinforced by additional data using
a specific Ser/Thr phosphatase inhibitor, Calyculin A
(Figure 3B). Ser/Thr phosphorylated proteins such as the
ERM (Ezrin/Radixin/Moesin) proteins were used here as a
positive control. As previously described (20), pERM levels were
dramatically increased in T lymphocytes treated with this drug.
We observed that both Fam65b isoforms exhibit a marked shift
toward higher apparent molecular weight species with Calyculin
A, suggesting that in resting T cells, Fam65b can be constitutively
phosphorylated on Ser and Thr residues. Importantly, pull-down
assays performed in parallel to compare the amount of RhoA
binding to Fam65b in cells treated or not with Calyculin A,
showed a clear decrease of RhoA binding with the drug (i.e.,
in conditions where Fam65b is highly phosphorylated). This
result therefore confirms a negative correlation between the
degree of Fam65b phosphorylation and its ability to bind
RhoA.
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FIGURE 2 | Fam65b KO T cells exhibit an exacerbated RhoA signaling pathway. (A) Top left panel: Example of detection of the amount of RhoA-GTP by flow
cytometry in lymph node T lymphocytes from WT (blue) or Fam65b KO (red) mice. Top right panel: RhoA-GTP levels from eight independent experiments are shown.
The intensity of the RhoA-GTP staining obtained in each experiment is normalized to the average values of WT mice. Bottom panel: The detection of the total amount
of RhoA in T cells shown by flow cytometry shows no difference between WT and Fam65b KO mice. (B) Top: After purification of T lymphocytes from WT or Fam65b
KO mice, expression of phospho-MLC (pMLC) and total MLC was analyzed by Western blot. Bottom: Quantification of the pMLC/MLC ratio measured in three
independent experiments. *p < 0.05, ***p <0.001.
We next aimed at identifying the Fam65b amino acids that
can be phosphorylated in physiological conditions using an
unbiased phospho-proteomic analysis. For this assay, we focused
our interest on the most abundant and shortest isoform 2 of
Fam65b whose sequence is fully included in the longer isoform
1. We have also previously shown that this isoform exhibits a
stronger affinity to RhoA than isoform 1 (11). We were able to
map nine serine residues whose probability of phosphorylation
was close to 100%, at positions 5, 21, 37, 166, 175, 341, 473, 474,
and 523 (Figure 3C). No threonine or tyrosine residues could be
identified in this assay.
Next, in order to determine the role of these residues in
Fam65b phosphorylation and its ability to bind RhoA, we
generated a mutant form of Fam65b called Fam65b(S9A) in
which all nine identified serine residues were mutated into
alanine. This construct was fused to GFP. We first checked
whether the shift of the molecule in resting T cells transfected
with the Fam65b(S9A)-GFP construct and stimulated with
CCL19 was still apparent. As shown in Figure 3D, no shift could
be observed upon stimulation, contrary to the WT Fam65b-GFP
protein.
We next used this mutant to determine to what extent Fam65b
phosphorylation impacts on its ability to bind RhoA. For this
purpose, plasmid constructs encoding for Fam65b WT or S9A
were transfected into the 293T cell line that does not express
endogenous Fam65b. The ability of Fam65b WT and S9A to
bind RhoA was tested in pull-down assays (Figure 3E). The
results show that the Fam65b(S9A) mutant binds RhoA more
strongly than the wild-type form of the molecule. Quantification
of the amount of Fam65b bound to RhoA in four independent
experiments indicated a 1.8-fold increase with the mutant
compared to the WT Fam65b protein. These results indicate that
Fam65b phosphorylation on serine residues upon CCL19T cell
stimulation is responsible for the dissociation of the Fam65b-
RhoA complex.
Control of Fam65b Localization by
Phosphorylation and RhoA Binding
It is well documented that RhoA shuttles between the cytosol,
where its association with GDI proteins maintains it in
an inactive state, and the plasma membrane, where it gets
activated by GEFs (1). Because Fam65b binds RhoA and
because the above results show that CCL19 stimulation modifies
the phosphorylation status of Fam65b, we next wondered
whether this post-translational modification also alters Fam65b
subcellular localisation. Using a cell fractionation assay, we
therefore studied whether CCL19 stimulation of T lymphocytes
that affects Fam65b phosphorylation levels, also changes its
distribution.
Primary T lymphocytes were stimulated or not with CCL19
and cytosol or membrane fractions were isolated (Figure 4A).
The degree of purity of each fraction was tested by blotting for
proteins expressed specifically in each compartment: Erk1/2 and
CD3-ε, respectively. Upon CCL19 stimulation, quantifications
of the amount of Fam65b present in the cytosol exhibited
an increase, with a concomitant decrease in the membranous
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FIGURE 3 | CCL19 stimulation phosphorylates Fam65b and controls Fam65b-RhoA interaction. (A) T cells were stimulated or not with 200 ng/ml of CCL19 for 2min.
The resulting lysates were incubated without (Control) or with Phosphatase (Pase) λ for 45min. A fraction of each samples was then analyzed by Western blot
immunoblotting, using an anti-Fam65b antibody that detects both Fam65b isoforms 1 and 2. The other lysate fractions were used for GST-Pulldown experiments with
recombinant GST-RhoA. Fam65b immunoblotting of pull-down samples allows detection of the amount of Fam65b bound to RhoA. (B) PBT were treated with 200 nM
Calyculin A (Cal A) or vehicle (DMSO) for 10min. A fraction of the whole cell lysates was directly analyzed by Western blot, whereas another fraction was used for a
GST Pull-down experiment with recombinant RhoA, as previously described. Antibodies against Fam65b, GST and pERM were used in these immunoblots. (C)
Amino acid sequence of Fam65b isoform 2. The serine residues identified by phosphoproteomics are underlined in bold. (D) Western blot analysis of WT and S9A
Fam65b-GFP proteins in PBT unstimulated or stimulated with 200 ng/ml CCL19 for 2min. (E) Left: Lysates from 239T cells transfected with WT or S9A Fam65b-GFP
constructs were incubated with beads containing recombinant GST-RhoA for GST Pull-down experiments. The amount of Fam65b bound to the beads was detected
by anti-GFP immunoblot. Right: Quantification of the binding of WT or S9A Fam65b-GFP. Fam65b band intensities in the pull-down fraction were normalized to their
expression in the total lysate. For each of the four independent experiments performed, the amount of binding of Fam65b-GFP WT to RhoA was set to 1. *p = 0.04.
fraction (Figure 4A, bottom). The same results were obtained for
both Fam65b isoforms 1 and 2.
This result raises the possibility that the Fam65b
phosphorylation observed upon CCL19 stimulation could
be responsible per se for the cytosolic accumulation of Fam65b.
To address this question directly, we analyzed the subcellular
localization of the non-phosphorylated Fam65b(S9A)-GFP
mutant transfected in the CEM T cell line that does not express
endogenous Fam65b. CEM cells exhibit a larger cytosol than
primary T cells and are thus more suitable for visualizing the
different subcellular regions by imaging techniques. Cells were
co-transfected with a CAAX-DsRed construct and stained
with DAPI to visualize in parallel the plasma membrane
and the nucleus, respectively. Images of individual cells are
shown (Figure 4B, top). The most striking feature that could
be obviously evidenced in these cell pictures was the strong
membrane localization of the non-phosphorylated S9A mutant
of Fam65b. By quantifying the intensity of the GFP signal
present in the cytosol and at the membrane in individual cells,
we were able to calculate a cytoplasm/membrane ratio for each
individual cell. Results showed that compared to GFP, this
ratio was lower for the WT Fam65b-GFP form indicating that
a fraction of Fam65b localizes at the plasma membrane, in
accordance with the cell fractionation assay shown previously
(Figure 4A). Most strikingly, this cytoplasm/membrane ratio
was strongly decreased with the S9A mutant. This result
indicates that Fam65b phosphorylation favors its cytosolic
distribution. In addition, we and others previously showed
that Fam65b mutations of Arg151 and Leu152 in Ala inhibited
RhoA binding (12, 21). When we introduced such RL mutation
in both WT and S9A Fam65b forms, one could observe that
the corresponding mutants adopt a cytosolic distribution.
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FIGURE 4 | Phosphorylation controls Fam65b shuttling between the plasma membrane and the cytosol. (A) Top: PBTs were stimulated or not with 200 ng/ml CCL19
for 2min before performing a cell fractionation assay. The obtained cytosolic and membranous fractions were then analyzed by Western blot using an anti-Fam65b
antibody as well as the following antibodies directed against: Erk1/2 and CD3-ε used as specific markers for the cytosol and the membranes, respectively. Bottom:
Quantification of the levels of expression of Fam65b isoforms 1 and 2 after normalization to controls of each compartment for each time condition (means ± SE from
five independent experiments). (B) Top: CEM cells were transfected with the GFP expression vector alone, Fam65b-GFP WT, Fam65b(S9A)-GFP, the non-RhoA
binding mutant Fam65b(RL)-GFP or the double mutant Fam65b(S9A, RL)-GFP together with pCAAX-DsRed to stain the plasma membrane in red. These cells were
then labeled with DAPI (blue) to stain the nucleus. The fluorescence microscopy images shown were randomly acquired at 60X magnification. Bottom: Quantification
of GFP intensity in the cytoplasm/plasma membrane of CEM cells. Each symbol corresponds to the analysis of one cell. A total of 15–35 cells per transfection
condition were included in this quantification. *p < 0.05, **p < 0.01, ****p <0.0001.
Altogether, this indicates that the preferential association of
Fam65b to the plasma membrane requires interaction with
RhoA.
Functional Analysis of Fam65b Actions
Downstream RhoA
In order to test the functional consequences of Fam65b and its
mutated forms on RhoA activity, we used the HBMEC cell line
transfected with the different Fam65b constructs. Indeed, in these
cells that do not express endogenous Fam65b, F-actin stress fibers
have been reported to be directly under the control of RhoA
(22). Thus, we analyzed the capacity of various Fam65b mutants
to interfere with the formation of F-actin stress fibers. Cells
were stained with phalloidin to visualize the actin cytoskeleton
network (Supplementary Figure 4, top) and the number of stress
fibers per cell was quantified (Supplementary Figure 4, bottom
left). Control cells transfected with GFP alone exhibited an
average of 13 stress fibers per cell. By contrast, cells expressing
the wild-type Fam65b form exhibited a marked decrease of actin
stress fibers, with the Fam65b(S9A) mutant inhibiting almost
completely their formation. Interestingly, the addition of the RL
mutation in both WT and S9A Fam65b constructs blocked the
inhibition of Fam65b on actin stress fibers generation. Therefore,
this indicates that Fam65b WT and S9A need to interact with
RhoA in order to inhibit the formation of stress fibers. In
addition, the quantification of the total amount of F-actin in these
different conditions clearly indicates that cells transfected with
the RhoA binding competent forms of Fam65b exhibit a strong
reduction in actin filaments staining (Supplementary Figure 4,
bottom right). This indicates that the loss of actin stress fibers
is not compensated by the generation of another type of actin
structure.
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FIGURE 5 | Fam65b inhibits the RhoA signaling pathway and T cell migration
in vitro. Quantification of the Transwell migration index in five independent
Transwell assays performed on CEM cells transfected with the indicated
GFP-tagged constructs. Each symbol corresponds to an independent
experiment. *p < 0.05, **p < 0.01, ***p <0.001.
Generally, we show here that, by inhibiting RhoA activity,
Fam65b affects two major downstream RhoA pathways
responsible for cytoskeletal alterations: actin polymerization and
stress fibers formation in adherent cells.
We next investigated the possible functional consequences
of these cytoskeletal alterations induced by Fam65b on T cell
migration. Once again, we used the CEM cell line to test the
effect of expression of the different mutants of Fam65b. We
first checked whether optimal CEM migration requires a fully
functional RhoA signaling pathway. For this, we used the well-
documented ROCK inhibitor Y27632 (23), as ROCK is a key
downstream target of RhoA to induce cell migration in various
cellular models (7). As shown in Supplementary Figure 5,
dampening ROCK activity in CEM cells strongly suppressed their
migration induced by the chemokine CXCL12.
Using this read-out, we thus checked whether expression
of WT Fam65b or Fam65b(S9A) had an effect. Both inhibited
T cell migration very efficiently (Figure 5), especially the S9A
mutant (70 vs. 45% inhibition, respectively). These inhibitory
effects were abrogated when Fam65b mutants bear the additional
RL mutation which precludes RhoA binding. Therefore, the
inhibitory effect of Fam65b on T cell migration requires its
ability to bind RhoA. Moreover, the non-phosphorylated and
membranous form of Fam65b is the most efficient one to reduce
T cell migration.
DISCUSSION
In this work, we show that Fam65b exerts a constitutive tonic
inhibition on RhoA activation in resting T lymphocytes. Indeed,
unstimulated T cells from Fam65b KO mice exhibit exacerbated
levels of active RhoA. The purpose of this study was then to
understand how the brake that Fam65b exerts on RhoA can be
relieved upon chemokine stimulation to allow RhoA activation.
We show here that the key event is the phosphorylation of
Fam65b by an as yet unidentified Ser/Thr kinase. The mode
of Fam65b inactivation by stimulus-induced phosphorylation
that we show here, is reminiscent of the one that operates on
classical GDI proteins. Indeed, it has been shown that GDIa
phosphorylation releases Rho GTPases that can then be activated
by GEF at the plasma membrane (24, 25).
In T cells, Fam65b phosphorylation will have at least two
connected consequences: (i) it directly decreases the affinity of
its interaction with RhoA and consequently, (ii) it favors the
shuttling of a fraction of Fam65b proteins from the plasma
membrane to the cytosol.
The reason why non-phosphorylated Fam65b is localized
at the plasma membrane is not clear yet. In addition to the
requirement for RhoA binding that we show here, there are
several hypotheses that could explain this particular distribution.
It has been suggested that the Fam65b protein contains BAR
domains, i.e., domains that promote membrane anchoring. This
would explain why, in the absence of this domain, Fam65b has
an essentially cytoplasmic localization (26). These domains are
recognized by sequence homology with proteins that are known
to have some. This method makes it possible to have an insight
into the probability of existence of these domains. The presence
of these BAR domains in Fam65b is nonetheless controversial
(27, 28). To confirm the existence of such domains, it would
be necessary to perform a crystallographic analysis of Fam65b,
which would confirm or invalidate this hypothesis. Another
hypothesis is that Fam65b binds to an unknown partner at
the level of the plasma membrane and that phosphorylation of
Fam65b alters its structure by the addition of a group creating a
negative charge which would make the interaction between the
two proteins weaker and release Fam65b from its membranous
location.
Our results show that the WT form of Fam65b, which is
known to be hypophosphorylated, is mainly located in the
cytosol and inhibits RhoA activation. We also show that the
mutant Fam65b (S9A) is not phosphorylated by chemokine
stimulation and is localized mainly at the plasma membrane.
Moreover, Fam65b (S9A) is more potent than Fam65b (WT) for
binding RhoA and inhibiting the RhoA pathway, and thus the
appearance of stress fibers in the HBMEC endothelial lineage
and migration in the T CEM line. Since RhoA is generally
considered to be activated at the level of the plasma membrane
by GEFs, it would seem logical that a more widely membrane-
bound form of Fam65b has a stronger inhibitory effect on the
activation of the RhoA pathway which originates at the plasma
membrane. Moreover, Fam65b (S9A) has a greater capacity than
Fam65b (WT) to bind RhoA in vitro. This greater affinity could
explain the fact that Fam65b (S9A) is also more effective than
Fam65b (WT) in inhibiting the migration of T lymphocytes.
Nevertheless, the inhibitory effect of these two Fam65b proteins
on the formation of stress fibers and migration also depends
on their ability to interact with RhoA since the introduction of
the RL mutation in the Fam65b (RL) and Fam65b (S9A, RL)
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suppresses the inhibitory effect of Fam65b on the formation of
stress fibers and onmigration. This observation is consistent with
the results previously published by our team showing that the
Fam65b-RhoA interaction is direct.
We and others have shown that Fam65b interacts with
the 14-3-3 chaperone protein (12, 21). 14-3-3 binds to the
phosphorylated form of Fam65b, so it is likely that 14-3-3 will
play a role in the regulation of the association of Fam65b and
RhoA. Indeed, there may be competition between RhoA and 14-
3-3 to bind Fam65b: non-phosphorylated form of Fam65b would
preferentially bind to RhoA, whereas the phosphorylated form
of Fam65b would tend to interact with 14-3-3, thus relieving
the brake that Fam65b usually exerts on RhoA in resting cells.
Fam65b could therefore be a new protein that takes part in the
cross-talk between 14-3-3 and RhoA signaling pathways, as has
been recently described for the interactions between the signaling
pathways regulated by 14-3-3 and Rac1 (29).
Many actors of the cytoskeleton intervene, by more or less
varied mechanisms, in the motility of cells and particularly of
the T lymphocytes. The localization of Fam65b at the membrane
could allow it to inhibit a membranous pool of RhoA and
to allow fast activation of this pathway during a chemokinetic
stimulation, since RhoA is already membranous and thus close
to the exchange factors which activate it.
It is also necessary for a cell to tightly control the expression
and activity of negative RhoA regulators such as Fam65b. Indeed,
our results show that overexpression of Fam65b inhibits the
RhoA signaling pathway, whereas knocking-out Fam65b greatly
increases the levels of active RhoA. In both cases however, T cell
migration is impaired, showing that Fam65b expression level is
key to allow optimal T lymphocyte motility both in vitro and in
vivo. Non-physiological levels of RhoA activity, either higher or
lower, may cause similar cellular defects. This is a typical feature
of Rho GTPases (30).
All these results are therefore in agreement with the
model that, under basal conditions, Fam65b is associated with
RhoA at the plasma membrane and that, after chemokine
stimulation, Fam65b is phosphorylated, dissociates from RhoA
and accumulates in the cytosol. The RhoA at the plasma
membrane can then be activated by GEF and induce downstream
signaling events required for T lymphocyte migration.
MATERIALS AND METHODS
Reagents
The calyculin A and Y27632 pharmacological inhibitors were
purchased from Merck. CCL19 and CXCL12 (both from
Peprotech) were used at the indicated concentrations.
Constructs
Fam65b-iso2 was amplified by PCR from the pFam65b-V5 vector
(31). The resulting PCR fragment was then introduced into
the pEGFP-N1 vector (Clontech). Point mutants of Fam65b
(RL: Arg151 and Leu152 in Ala and S9A: Ser 5, 21, 37, 166,
175, 341, 473, 474, 523 in Ala) were obtained by site-directed
mutagenesis (QuikChange kit, Agilent Technologies). Plasmid
pCAAX-DsRed encoding a red fluorescent protein capable of
labeling the plasma membrane of living cells was provided by F.
Niedergang (Cochin Institute).
Cells
Peripheral Blood CD3+ T lymphocytes (PBTs) were purified
from the blood of healthy donors provided by the Etablissement
Français du Sang on Ficoll gradients before performing a
negative selection sorting with the EasySep Human T cell
Isolation kit (Stem Cell). The cells were then cultivated in RPMI
medium supplemented with 10% of humanAB serum, antibiotics
(penicillin 50 U/ml, Streptomycin 50µg/ml, Gibco), glutamine
(4mM, Gibco) and sodium pyruvate (1mM, Gibco).
Murine CD3+ T lymphocytes were purified with the EasySep
Mouse T cell Isolation kit (Stem Cell) using cell suspensions
coming from the spleen and lymph nodes of WT or Fam65b
KOmice. Before sorting, red blood cells present with splenocytes
were lysed in the ACK buffer (155mM NH4Cl, 10mM KHCO3,
and 1mM EDTA, pH 7.3).
CEM cells (leukemic cell line) were cultured in RPMI
medium supplemented with 10% fetal calf serum (Dominique
Dutscher, France), sodium pyruvate (1mM, Gibco), glutamine
(4mM, Gibco), and antibiotics (penicillin 50 U/ml, Streptomycin
50µg/ml, Gibco). 293T cells and HBMEC (human bone marrow
endothelial cells; gift from S. Bourdoulous, Cochin Institute) were
cutured in DMEM containing the same additives.
Fam65b Knock-Out (KO) Mice
In order to obtain a model of mouse deficient for Fam65b, two
lox sequences were first introduced by PCR on both sides of
exons 3 and 4 of the Fam65b gene (Supplementary Figure 1A).
Linearized targeting vector was transfected into ES cells.
Homologous recombinants were identified by Southern-blot
analysis, and were implanted into foster mothers. Chimeric mice
were bred to C57BL/6J mice, and the F1 generation was screened
for germline transmission. Mice carrying the floxed allele of
Fam65b were backcrossed to C57BL/6J for five generations using
the speed backcross technology (Charles River) to achieve 99.61%
identity with C57BL/6J genome. Animals carrying such lox sites
on their two alleles (Fam65blox/lox mice) were then crossed
with transgenic mice expressing the Cre recombinase under
the control of the CD4 promoter (provided by S. Amigorena,
Institut Curie, Paris). The resulting Fam65blox/lox x Cd4-Cre
animals give rise to mice exhibiting a T cell-specific deletion of
Fam65b (Fam65b KO). Fam65blox/lox animals that do not express
Cd4-Cre were used as controls (WT mice) in all the reported
assays. For each experiment, the WT and Fam65b KO mice
were systematically sex-matched and littermates. All mice were
maintained under specific pathogen-free conditions. All animal
experimentation was conducted in accordance with institutional
guidelines.
DNA Transfections
3.106 293T cells per condition were transfected with 10 µg of
plasmid DNA into 10 cm Petri dishes using lipofectamine 2000
(Invitrogen) according to the protocol provided by the supplier.
The cells were used 48 h later for further experiments.
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5.105 HBMEC per cuvette were washed in PBS and
resuspended in 100 µl of Cell Line Nucleofector Solutions V
(Lonza). These cells were transfected by nucleofection using the
U-015 program (Lonza) with 3–4 µg of DNA.
2.106 or 5.106 CEM cells per condition were washed in PBS
and resuspended in 100 µl of Cell Line Nucleofector Solutions V
(Lonza). These cells were transfected by nucleofection using the
C-016 program (Lonza) with 5 or 10 µg of DNA, respectively.
10.106 human primary T cells per condition were washed in
PBS and resuspended in 100 µl of Human T Cell Nucleofector
Solution (Lonza). These cells were transfected by nucleofection
using the U-014 program (Lonza) with 10 µg of DNA.
All cells transfected by nucleofection were used for functional
assays after an overnight incubation time.
Western Blots
Human PBTs or mouse T cells stimulated or not with 200 ng/ml
CCL19 or CXCL12 (Peprotech) for 2min were lysed for
30min at 4◦C in RIPA lysis buffer (50mM Tris HCl pH 8,
150mM NaCl, 0.1% SDS, 1% NP-40, 0.5% deoxycholate, 2mM
EDTA) supplemented with a cocktail of protease inhibitors
(EDTA-free Complete Inhibitors, Roche) and phosphatases
(PhosSTOP, Roche). The nuclei and cell debris were removed
by centrifugation at 14,000 rpm for 10min at 4◦C. The lysates
were diluted in Laemmli buffer (500mM Tris pH 6.8, 10%
SDS, 10% glycerol, 5% β-mercaptoethanol, 10% bromophenol
blue) and the proteins were then denatured by heating for
5min at 100◦C. Next, the samples were run on an 8 or 15%
acrylamide gel. Molecular weight markers (Fermentas) were also
run in parallel. The proteins separated by electrophoresis were
next transferred on a PVDF membrane (GE Healthcare Life
Sciences). After 1 h of saturation in T-TBS (0.1% Tween 20
(Sigma), 10% TBS 10X) containing 5% milk, the membrane was
incubated overnight at 4◦Cwith the following primary antibodies
diluted in T-TBS containing 1% BSA: anti-β-actin (clone AC-74,
Sigma), anti-GFP (rabbit polyclonal antibody # TP401, Torrey
Pines Biolabs), anti-Fam65b (clone 2F6-1A11, Abnova), anti-
Myosin Light Chain 2 (rabbit polyclonal antibody # FL172,
Santa Cruz) and anti-p-Myosin Light Chain 2 (S19) (rabbit
polyclonal antibody # 3671, Cell Signaling Technology). After 3
rapid washes in T-TBS with the SNAP system id. 2.0 (Millipore),
the membrane was incubated for 10min with the relevant goat
anti-mouse or anti-rabbit secondary antibody coupled to HRP
(# 115-035-146 or # 111-035-144, Jackson Laboratory). After
aspiration of the solution containing the secondary antibody, the
membrane was washed 3 times with T-TBS. The revelation was
performed with an ECL kit (GE Healthcare Life Sciences). The
emitted signal was detected by a camera (Fusion FX7, Vilbert
Lourmat).
Pull-Down Assays
GST pull-down experiments were performed on 293T cells or
PBTs (50.106 cells per condition) stimulated in 1ml of HBSS
containing 200 ng/ml CCL19 for 2min or 200 nM Calyculin A
for 10min at 37◦C. The cells were then lysed for 30min at 4◦C
in pull-down buffer (100mM NaCl, 50mM Tris HCl, 1% NP-
40, 10% Glycerol, 2mM MgCl2) supplemented with protease
inhibitors and phosphatases inhibitors in most experiments.
After a 10min centrifugation step at 14.000 rpm at 4◦C, the
supernatant was treated or not with Phosphatase λ (Merck)
according to the manufacturer protocol. A fraction of the
supernatant was then set aside as a control of whole cell
lysate proteins and the rest of the supernatant was incubated
with Sepharose beads coated with Glutathione (GE Healthcare)
with shaking for 1 h at 4◦C to eliminate protein non-specific
binding to beads (pre-clearing step). In parallel, Glutathione
beads were incubated with recombinant GST or GST-RhoA
(Cytoskeleton) proteins in PBS with stirring for 1 h at 4◦C.
Alternatively, beads directly coupled to GST or GST-RhoA
(Cytoskeleton) were also used. After washing the beads, the
pre-cleared lysates were then incubated with the Glutathione
beads loaded with GST or GST-RhoA for 2 h at 4◦C under
continuous rotation. The beads were then washed 3 times in
pull-down buffer and diluted in Laemmli buffer. The proteins
were next separated by SDS-PAGE and revealed by Western
blotting with the following antibodies: anti-Fam65b, anti-GST
(# 06-332, Upstate Biotechnology Inc.), anti-pERM (rabbit
polyclonal antibody # 3141, Cell Signaling Technology) or anti-
GFP.
Phosphoproteomics
For phosphoproteomic experiments, 400.106 PBT or 293T cells
transfected with the isoform 2 of Fam65b-V5 were used. PBTs
were stimulated at 50.106/ml for 2min with 200 ng/ml CCL19
at 37◦C, and the cells were lysed for 30min at 4◦C in pull-
down buffer supplemented with proteases and phosphatases
inhibitors. After 10min of centrifugation at 14,000 rpm at
4◦C, the supernatant was incubated with 10µg/ml anti-Fam65b
antibody (clone 3J7, Santa Cruz) for PBTs, or an anti-V5 antibody
(# R960-25, Invitrogen) for 293T cells. After 5 h of incubation
with constant stirring at 4◦C, magnetic beads coupled to Protein
G or Protein A (Dynabeads, Invitrogen) for PBTs or 293T cells
respectively, were added to the samples and incubated for 1 h
with agitation at 4◦C. The beads were thenwashed 3 times in pull-
down buffer, and resuspended in Laemmli buffer. The proteins
were separated by electrophoresis migration on an 8% acrylamide
gel, stained with Coomassie blue, and the bands of interest
were cut, processed and analyzed by Benjamin Thomas (Central
Proteomics Facility, Sir William Dunn School of Pathology,
University of Oxford, United Kingdom). Data were analyzed
using PD1.4, Mascot search, PhosphoRS and Percolator. Protein
coverage was 97% and only phospho sites whose probability was
close to 100% was considered to be a phosphorylated amino
acids.
Cell Fractionation
30.106 PBT were resuspended in 1ml of HBSS and stimulated
in the presence of 200 ng/ml CCL19 for the indicated times
at 37◦C. The cells were then centrifuged, and the pellet
resuspended in 200 µl of cold hypotonic buffer (10mM KCl,
10mM Hepes, 5mM MgCl2) supplemented with proteases and
phosphatases inhibitors, and 3.8µm diameter beads (SPHERO
Polystyrene Particles). The samples were then allowed to go
through a syringe mounted with a 30G needle eight times.
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After 10min of centrifugation at 200 g and 4◦C, the supernatant
was transferred to a new tube and centrifuged for 45min at
20000 g at 4◦C. The supernatant containing the cytosolic fraction
was recovered in a new tube and the protein concentration
was measured. The pellet was resuspended in 50 µl of lysis
buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-
40) supplemented with proteases and phosphatases inhibitors.
After 20min of incubation at 4◦C with vigorous stirring and
centrifugation for 45min at 20,000 g at 4◦C, the supernatant
containing the membrane fraction was recovered, and the pellet
resuspended in a solution of 1% SDS in H2O supplemented with
proteases and phosphatases inhibitors. After 20min incubation
at 4◦C with vigorous stirring, this solution was recovered. It
constitutes the insoluble or cytoskeletal fraction. The proteins
contained in these different fractions were then separated by
SDS-PAGE and sequentially revealed by Western blotting with
antibodies against Fam65b (clone 2F6-1A11, Abnova) and the
following antibodies: Erk1/2 (rabbit polyclonal antibody #V1141,
Promega) and CD3-ε (clone UCHT1, BD Biosciences) used
as specific markers to control the purity of the cytosolic and
membranous fractions, respectively. The amount of isoforms
1 and 2 of Fam65b in the different fractions was quantified
by measuring the Fam65b bands intensities divided by the
markers bands intensities in each condition, using the ImageJ
software.
Flow Cytometry
For intracellular staining of active RhoA, T cells from WT or
Fam65b KO mice were washed in cold PBS, fixed with 4% PFA
(Electron Microscopy Sciences), centrifuged for 3min at 3,000
rpm at 4◦C and resuspended in permeabilization buffer (PBS,
0.5% saponin, 5% FCS, 4mM NaN3) with 1/100 anti-RhoA-
GTP antibody (# 26904, NewEast Biosciences). After 30min of
incubation at 4◦C, the cells were washed in cold PBS containing
5% FCS and then incubated in permeabilization buffer with a
secondary antibody directed against mouse IgG coupled to a
fluorophore for 30min at 4◦C. After washing, the fluorescence
of the cells was measured on a FACScan (Becton Dickinson).
The staining for total RhoA was carried out in parallel with
a similar protocol using an anti-RhoA antibody (# ARH03,
Cytoskeleton).
Microscopy
Transfected live CEM cells stained with DAPI were analyzed by
fluorescencemicroscopy with a 60X immersion objective (Eclipse
TE3200, Nikon). The images were collected using a cooled CCD
camera (CoolSNAPfx, Ropper Scientific) and analyzed with the
ImageJ software. Quantification of the subcellular localization of
the Fam65b mutants was performed according to the formula:
GFP fluorescence intensity in the cytoplasm (region that is
neither stained with DAPI nor CAAX-DsRed)/GFP Intensity
at the plasma membrane (region stained by the CAAX-DsRed
Probe).
Transfected HBMEC cells were fixed with 4% PFA and
then washed in washing buffer (PBS, 1% BSA). Next, the cells
were permeabilized in PBS containing 0.1% saponin and 0.2%
BSA, and then incubated for 45min at room temperature
with Phalloidine-TRITC (# P1951, Sigma) to stain the actin
microfilaments. FluorSave (Calbiochem) was used as a mounting
medium. For each transfectant, the number of stress fibers as
well as the total F-actin staining intensity were quantified using
ImageJ.
3D Immunofluorescence
Twenty minutes after adoptive transfer, 3D immunofluorescence
(3-DIF) was performed (15). Hundred microgram anti–L-
selectin (clone Mel-14, Stem Cell) and 5 µg Alexa Fluor
633-conjugated anti-PNAd (clone MECA-79, BioLegend) were
injected intravenously. Twenty minutes later, mice were killed
using CO2, perfused with 5ml cold PBS, and fixed in 10ml
cold 1% PFA/PBS. Peripheral lymph nodes (PLNs) were collected
and manually cleaned from surrounding fat tissue under a
stereomicroscope. After overnight fixation in PBS/1% PFA, PLNs
were embedded into 2% (weight/vol) agarose low gelling point
(Sigma), dehydrated in methanol for 24 h, and cleared for
at least 2 days in benzyl alcohol-benzyl benzoate (1:2 ratio).
Blocks of agarose-embedded PLNs were imaged using a 2PM
setup (TrimScope; LaVision Biotec, Bielefeld, Germany). The
absolute number of lymphocytes labeled with each dye was
counted using Volocity software (PerkinElmer). Visual analysis
of individual z-sections was used to determine the position of
individual cells relative to the HEV network. After reconstruction
of the lymph node in 3-DIF, the percentage of T cells inside
or near the HEVs was also quantified as described (14). All
animal work has been approved by the Cantonal Committee
for Animal Experimentation and conducted according to federal
guidelines.
Transwell Migration
CEM cells either pre-incubated with DMSO or 5µM Y27632
(Calbiochem) overnight or transfected with different plasmids
were deposited in the upper compartment of a Transwell
insert (pore diameter: 5µm; Nunc). The lower compartment
contained no chemokine or 200 ng/ml CXCL12. After 3 h
of incubation, the inserts were removed, an equal amount
of calibration beads (Flow-Check Fluorospheres, Beckman
Coulter) was deposited in the wells, and the number of
cells having migrated to the lower compartment relative
to the number of beads was quantified by flow cytometry
(FACS Calibur, BD).
For Y27632 experiments, migration was quantified as
the number of migrating cells/total cell number. For each
transfectant, an eventual bias in cell migration due to Fam65b
expression was quantified by calculating the following formula:
migration index = % of migrating GFP+ cells/% of migrating
GFP− cells.
Two-Photon Microscopy of Popliteal
Lymph Node
PLNs purified from WT or Fam65b KO mice were loaded with
3µM CMFDA, 5µM CMAC or 2.5µM CMTMR fluorescent
probes for 20min at 37◦C. 5.106 cells of each population were
then mixed with a 1:1 ratio and injected intravenously in a
recipient wild-type C57BL/6J mouse. Twenty-four hours after
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injection, the popliteal lymph node was exposed and visualized
by 2-photon microscopy (TrimScope system equipped with a
20X lens Olympus BX50WI fluorescence microscope). Images
were acquired every 20 s for 20–30min. The T cell zone was
identified by the presence of HEV labeled after injection of
15 µg MECA-79-A633 antibody in the recipient mouse. The
reconstruction and analysis of the images were performed with
the software Volocity. Only T cell trajectories in the lymph node
parenchyma were considered, and cells leaving or approaching
the HEV were not taken into account in order to avoid
abrupt changes of speed. Several parameters were quantified:
migration speed, meandering index, directional changes and
motility coefficient.
Statistics
Significant differences between the groups were assessed using
unpaired Student t-test or theMann-Whitney test calculated with
the Prism 5 software (GraphPad Software).
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Supplementary Figure 1 | Generation of mice with T cell-specific deletion of the
Fam65b gene. (A) Schematic presentation of original allele (+), targeting vector,
the recombinant allele, the floxed allele (Fam65b) and the invalidated allele
(Fam65b). The position of the forward (F) and reverse (R) primers used for
genotyping are indicated as black arrows on the original allele. Filled blue boxes
represent the exons 3 and 4 of the Fam65b gene. The locations of
restriction-enzyme sites (XhoI, PacI, MluI, NotI and AscI) are indicated. Loxp and
Frt sites are showed as red arrowheads and filled green boxes, respectively. The
hygromycin resistance cassette is shown as a white box. (B) PCR genotyping of
the floxed Fam65b allele and the original allele.
Supplementary Figure 2 | Fam65b KO mice do not exhibit alterations in
thymocyte and T cell numbers. (A) Western blot analysis of Fam65b expression in
thymocytes and splenic T cells from WT or Fam65b KO mice. The anti-β-actin
immunoblot was used as a loading control. (B) Similar Western blot analysis using
splenic non-T cells from WT or Fam65b KO mice. (C) WT of Fam65b KO
thymocytes and T lymphocytes purified from Peyer’s patches, spleen, peripheral
(p) or mesenteric (m) lymph nodes (LN) were counted. Each dot represents a
single mouse.
Supplementary Figure 3 | CXCL12 or CCL19 stimulation induces a shift of
Fam65b bands. Western blot analysis of Fam65b isoforms 1 and 2 upon CCL19
or CXCL12 stimulation of human PBTs.
Supplementary Figure 4 | Fam65b inhibits the RhoA signaling pathway. Top:
HBMEC cells were transfected with expression vectors encoding GFP alone,
Fam65b (WT), Fam65b(S9A), Fam65b(RL), or Fam65b(S9A, RL) all tagged with
GFP. The cells were then labeled with phalloidin to visualize the actin filaments by
microscopy. The representative images shown were acquired with a 60X
magnification. Quantification of the number of stress fibers (bottom left) and
F-actin staining intensity (bottom right) in HBMEC cells (20 ≤ n ≤ 30). ∗∗p < 0.01,
∗∗∗p <0.001, and ∗∗∗∗p <0.0001.
Supplementary Figure 5 | ROCK inhibition largely suppresses T cell migration.
Quantification by flow cytometry of the percentage of CEM cells that have
migrated through the Transwell insert in the presence or absence of Y27632
(ROCK inhibitor, gray bars) or DMSO (vehicle, black bars) upon stimulation (+) or
not (–) with 200 ng/ml CXCL12. Means ± SE from three independent experiments.
∗p < 0.05.
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